A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH.

Objectives: \- To study the natural history of PAH.

Eligibility: * Individuals at least 18 years of age who have PAH. * Healthy volunteers at least 18 years of age.

Design: * Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center. After the first visit, they will return in 6 months and then yearly or every other year for as long as the study continues. * The first visit will take up to 3 days. It will involve the following tests: * Physical exam and medical history * Blood and urine samples * Heart and lung function tests and imaging studies * Six-minute walk test * Questions about exercise and physical activity * Healthy volunteers will have only one visit to the Clinical Center, during which they will undergo screening tests, and complete many of the same tests as patients with PAH

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: t
View:

⁃ The following parameters on RHC are required to meet the hemodynamic definition of PAH (NYHA/WHO Group I PH):

• mean pulmonary artery pressure of greater than 25 mmHg at rest,

• pulmonary capillary wedge pressure of less than or equal to 15 mmHg (or a left ventricular end-diastolic pressure of less than or equal to 12mmHg) and

• pulmonary vascular resistance of greater than 3 Wood units (240 dyn s cm(-5)).

⁃ For patients with suspected PAH (Group I PH) who have not undergone a RHC and/or additional testing to confirm the diagnosis, this testing will be completed as clinically indicated under a procedural consent. If clinically indicated (diagnostic) testing indicates that the subject with suspected PAH does not in fact meet standard criteria for PAH (Group I PH), then the subject will be removed from the study.

⁃ Any healthy man or woman who is the appropriate age and sex for matching to a PAH patient

• Must be eligible for MRI and Gadolinium Based MRI studies

• Must be eligible for CT and Iodine Based Contrast CT studies

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Grace M Graninger, R.N.
ggraninger@cc.nih.gov
(301) 496-9320
Backup
Michael A Solomon, M.D.
msolomon@cc.nih.gov
(301) 496-9320
Time Frame
Start Date: 2013-07-15
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 270
Treatments
Healthy Volunteers
Enroll up to 120 healthy volunteers, in order to obtain approximately 55 evaluable healthy volunteers matched to pulmonary arterial hypertension subjects for age and sex
Pulmonary Arterial Hypertension Subjects
150 subjects with pulmonary arterial hypertension; male or female, age grater than or equal to 18 99 years
Related Therapeutic Areas
Sponsors
Leads: National Institutes of Health Clinical Center (CC)

This content was sourced from clinicaltrials.gov